Brilique, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with ? acute coronary syndromes (ACS) or ? a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event